41 results on '"Gerber, D.E."'
Search Results
2. TTFields (Tumor Treating Fields) associés au traitement standard dans les cancers du poumon non à petites cellules métastatiques en progression après platine : étude internationale, randomisée de phase 3 LUNAR
Catalog
Books, media, physical & digital resources
3. Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer
4. 122P Casdozokitug (casdozo, SRF388), a first-in-class IL-27 targeting antibody, as monotherapy (monotx) or in combination with pembrolizumab (pembro) in treatment-refractory non-small cell lung cancer (NSCLC)
5. P1.27-04 Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: Bronchioloalveolar Carcinoma of the Lung
6. OA22.05 TTFields and Immune-Checkpoint Inhibitor in Metastatic Non-Small Cell Lung Cancer: PD-L1 Subgroups in the Phase 3 LUNAR Study
7. P2.28-03 Symptomatic vs. Asymptomatic SARS-CoV-2 Infection Rates in Lung Cancer: Longitudinal Nucleocapsid Antibody Analysis
8. P2.06-12 The Safety and Efficacy of Durvalumab as 1st Line Therapy in Patients with Advanced NSCLC and ECOG PS of 2
9. 1st Line Pembrolizumab in Treatment of Stage IV NSCLC Patients – A Pattern of Failure Analysis with Associated Survival Outcomes
10. P1.09B.04 Impact of BMI on TTFields in Patients with Mnsclc: Post-hoc Analysis from the Phase 3 LUNAR Study and Simulation Model Data
11. OA06.03 Serological Response to SARS-CoV-2 Vaccination in Patients Lung Cancer: A Mount Sinai-Led Prospective Matched Controlled Study
12. Patterns of Failure in Metastatic Non-Small Cell Lung Cancer Patients After Initiation of Pembrolizumab
13. 1255TiP CheckMate 73L: A phase III study comparing nivolumab (NIVO) plus concurrent chemoradiotherapy (CCRT) followed by NIVO ± ipilimumab (IPI) versus CCRT followed by durvalumab (DURV) for previously untreated, locally advanced (LA) stage III non-small cell lung cancer (NSCLC)
14. Tracking the Non-Enrolled: Lung Cancer Screening Patterns Among Individuals Not Accrued to a Randomized Clinical Trial
15. Implementation of a Lung Cancer Screening Program in a Majority-Minority, Safety-Net Health System: Completion Rates and Radiological Findings in the First Two Years
16. Phase Ib KEYNOTE-200: A study of an intravenously delivered oncolytic virus, coxsackievirus A21 in combination with pembrolizumab in advanced NSCLC and bladder cancer patients.
17. Résultats à 5 ans des essais cliniques randomisés de phase III CheckMate (CM) 017/057 : nivolumab vs docétaxel dans le cancer bronchique non à petites cellules (CBNPC) avancé après un traitement antérieur
18. Phase IB KEYNOTE-200: A study of an intravenously delivered oncolytic virus, coxsackievirus A21 in combination with pembrolizumab in advanced NSCLC and bladder cancer patients.
19. Phase Ib KEYNOTE-200: A study of an intravenously delivered oncolytic virus, coxsackievirus A21 in combination with pembrolizumab in advanced NSCLC and bladder cancer patients
20. 98P Trends in and impact of hospital-acquired adverse events in patients with lung cancer undergoing lung resection
21. 197TiP A phase 1/2 trial of selinexor combined with docetaxel for previously treated, advanced KRAS mutant non-small cell lung cancer
22. Proteomic signature analysis and application in clinical development of the novel phosphatidylserine-targeting immunotherapy, bavituximab
23. LBA40 - Phase Ib KEYNOTE-200: A study of an intravenously delivered oncolytic virus, coxsackievirus A21 in combination with pembrolizumab in advanced NSCLC and bladder cancer patients
24. 197TiP A phase 1/2 trial of selinexor combined with docetaxel for previously treatedadvanced KRAS mutant non-small cell lung cancer
25. 3096 First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses
26. Effect of Prior Cancer on Outcomes in Advanced Lung Cancer: Implications for Clinical Trial Eligibility and Accrual
27. Acquired Resistance to Afatinib in EGFR-Mutant Lung Cancer
28. Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Combination With Platinum-Based Doublet Chemotherapy (PT-DC) in Advanced Non-Small Cell Lung Cancer (NSCLC)
29. Randomized Phase 2 Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Single-Agent Chemotherapy in Previously Treated KRAS Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)
30. First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status
31. Nivolumab (Anti-Pd-1; Bms-936558, Ono-4538) in Combination with Platinum-Based Doublet Chemotherapy (Pt-Dc) or Erlotinib (Erl) in Advanced Non-Small Cell Lung Cancer (Nsclc)
32. 30P - Proteomic signature analysis and application in clinical development of the novel phosphatidylserine-targeting immunotherapy, bavituximab
33. A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) Combined with Erlotinib for Patients with Recurrent Non-small Cell Lung Cancer (NSCLC)
34. 1054PD - Nivolumab (Anti-Pd-1; Bms-936558, Ono-4538) in Combination with Platinum-Based Doublet Chemotherapy (Pt-Dc) or Erlotinib (Erl) in Advanced Non-Small Cell Lung Cancer (Nsclc)
35. Meeting the diverse needs of clients in the community: Effective use of the referral process
36. Understanding contemporary health and welfare services: The Social Security Act of 1935 and the Public Health Service Act of 1944
37. Emendations in the Odes of Pindar : an historical analysis
38. Menander’s Dyskolos
39. Tumor Treating Fields (TTFields) Therapy with Standard of Care in Metastatic Non-small Cell Lung Cancer Following Progression on or after Platinum Therapy: Global, Randomized, Pivotal Phase 3 LUNAR Study.
40. Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
41. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.